Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.875p 7.50p 9.00p - - - 0 07:41:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.2 -0.5 -0.8 - 4.63

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Takeover Rumours

Physiomics (PYC) Share Charts

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart

Intraday Physiomics Chart

Intraday Physiomics Chart

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
18/1/201808:04Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni260
17/1/201821:42PHYSIOMICS plc Virtual Tumor platform4,866
01/12/201719:18RGP NEXT MULTI BAGGER TODAY 50p4
01/12/201707:35Timbeeerrr back to reality -
23/3/201718:18Physiomics with Charts & News13,676

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-01-17 17:26:228.0089,2257,138.00O
2018-01-17 17:09:527.50106,7008,002.50O
2018-01-17 16:30:037.9350,8134,026.93O
2018-01-17 16:29:418.0425,0002,010.00O
2018-01-17 16:29:387.6575,0005,737.50O
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 7.88p.
Physiomics Plc has a 4 week average price of 6p and a 12 week average price of 0.93p.
The 1 year high share price is 32p while the 1 year low share price is currently 0.93p.
There are currently 58,785,394 shares in issue and the average daily traded volume is 1,624,756 shares. The market capitalisation of Physiomics Plc is £4,629,349.78.
pwhite73: bellesimo PYC and PCGE are two different animals. PYC is an actual business PCGE is not (yet). As with all AIM stocks one has to separate the company from its listing and look at each on its own merits. PYC has been listed just before Noah built his ark. The company rakes up losses year after and it is questionable whether they have a commercial product. The directors wages are very modest compared to normal AIM executive pay. PYC does not play the stock market game. The company only makes announcements when required and never engages in one to one chats with shareholders outside of official meetings. You'll never find them on Proactive Investor or in any stock related media outlet. That is one of the major criticisms PI shareholders have leveled at the company for years. They never promote themselves outside of their industry. Prior to the update on 28/11/2017 the share price was trading at 1p to buy and this was after a consolidation about a year previously. The shares rushed up to 32p on BB speculation of multi-million contracts to be announced soon. The company was forced to issue a statement reiterating what they had said on 28/11/2017. Yet still some people refused to believe. All the froth has now died down and the shareprice is slowly but surely returning to from whence it came. There are still those that are saying "just wait until the next contract is announced". Even if one is announced PYC is not an early stage drug company that has a promising pipeline that can be sold on for millions. It is just a computer simulation company. It has nothing direct to sell to the general public it effectively relies on companies like Merck to adopt their software or their finished. Merck have companies like PYC over a barrel and they know it. Low volume is the normal order of the day with this company. On 27/11/2017 the day before the announcement there was just two trades, sells for 0.95p. The stock is still up by a whopping 650% from 28/11/2017. These are PIs still holding at prices in the mid teens but can't force themselves to sell. The market cap is about £4m. People think its cheap but its way overpriced for a company of this size, what it does and its prospects. These are just my views but I can see no reason why the stock will stay up 650%. The MM will drip drip short the stock down to about 2p - 3p and there it will stay. The other thing to bear in mind is that once the hot money is gone on an AIM stock it never really returns. Best of luck if you're holding.
margic: It's a good thing for the PYC share price that eyes have just come off this. As buyers start to return this can move very very quick before the herd arrive and when the herd arrive we spike. Signal to take profit and re-load as the herd exit with their losses and smaller profits. Hope to see this 10p+ before volumes really pick up. Keep watch as PYC can flash bang wallop!
the stigologist: Todays VAL Valirx news on VAL201 is also great news for PYC. Expect PYC share price to follow VAL up
margic: Great stuff mate and exactly what I was hoping for, you've opened the doors for everyone to take note and find where to search, it's research and posts like that, that can move a stock and why not, there new information to see for investors to start predicting a value and assessing the share price tools to decide if PYC represents value. Centara is a great example, I highly doubt PYC would be taken out for anywhere near that figure based on the past but then again, was it here I read the directors have been ousted? That might change the picture. The bod I remember for years ago were no good to share holders but then again, why would you want long term shareholders when you have a big big play behind closed doors and a shocking share price. Price makes the mouth water now. 11.5p circa £6mil market cap, in a market that can quickly add £50mil valve on anything material that investors can put there eyes on. Even the $32mil take over in 2012 coming out of the burst. More money is spent now and it doesn't take much for a big boy to offer £35-50mil for a small slice, it helps them balance their spending. As I understand it, big pharmacy have a budget quota that must be spent year on year on certain aspects of the business and accumulating businesses, investment partnerships, support and R&D have the highest budgets set in both fiscal cash and time. These budgets. I may be wrong but GSK used to spend like 1bil dollars min a year on failed products before the 80's even. Certainly with now only 57odd mil shares in circulation this is a good time for PYC. I'm sure they can prove the markets cap to £12-15mil and then raising money to boost the line will become comfortable. Unless a take over offer happens out of no where you'd have to expect PYC to place just over 100mil shares, but it's very possible they could secure £10-30mil doing that. Big money for them, not sure they've ever had that at their disposal. As always it will be down to the bod and how soon they want to make their money. Many old money directors have 50-75years for their plays to come good.Is there any key news expected from the faithful? How do you see the BOD moving the company going forward, has anyone meet them or heard them speak? Thanks for the informative stuff stig. I'm only just flirting back in the aim market, I'm a technical trader now with currency's but I do like the aim. It seems now is like 2007-2011 all over again. Rises do seem much bigger. A good start for me has been some of the oldies im familiar with have been squeezed almost to the max and everything is jumping like true penny stocks should.PYC for starters, great news, big share price jump, hype, 57 something mil shares £6mil value, same as always, jumped in with 3mil market cap, can always go £12-15mil outta now where £35-50mil on transformational news, and £100mil + on a well sourced city take over rumour or bid. Bid less likely in normal terms but then again, Takeovers in the Pharma game are normally as good if not better than the tech industry. Disney splashing out £34bil, for essentially parts of a business, imagine what big pharmacy made will pay to wrap a deal up quick. It's not a ramp but I do know if GSK want a business they think a rival will want, they make an offer that won't be matched to conduct a move super quick. If PYC was valued by a proper surveying team at say £65mil (figure I've come up with based off others) , and no one was interested then it's a 20mil offer for part. If other firms are interested it's £80mil+, if a major rival is sniffing, £150-180mil+ plus part retention, if they feel a rival will bid, they'll re-visit alternatives, if they believe PYC to be better than all the rest, then you could be actually looking £500mil + you get a bidding war on that, who knows from there. That's how I see it.
stephen2010: As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
pwhite73: Jenny The MM will stop you buying if they have enough buy orders from professional investors to assure them the share price will be rising beyond your buy price. Conversely the MM will stop you selling if they have enough sell orders from professional investors to assure them the share price will be falling below your sell price. This is because there is a hierarchy in the city. Professional investors take precedence over Joe Blogg PIs like you are I. When PYC issued the qualifying RNS no PIs could get out. With regards to some of the vitriol against me and why I'm not retired instead of posting on a bulletin you can liken it to someone telling their doctor - "if you know so bloody much about the human body why were you off sick last week when I needed to see you urgently. The shares are still spiking due to shorts closing. Be careful if you intend to buy.
pwhite73: The share price is not rising because of buyers. The MM move the share price to burn whoever they can. Other institutions would have been shorting the stock so the price goes up to burn them. When they've settled they then turn their attention to PI who are still holding profits from last week. As the volumes reduce the share price will return to about 1 - 2p.
the stigologist: #PYC Physiomics Share Price : 8p Shares O/S : 57m Mkt Cap : £4.8m Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials. This optimisation improves the efficacy of combinations in pre-clinical xenografts. The company is also developing: Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials. Cardiac toxicity prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process. Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects. Physiomics plc works with partners from both small and large pharmaceutical and biotechnology companies since 2002. These include Merck Sharpe & Dohme Corp., Eli Lilly, Merck Serono, Sareum, Institute of Cancer Research, Cancer Research Technology, Cyclacel Pharmaceutical and ValiRx. Fee-for-service, licensing and revenue sharing options are available. On November 28th PYC issued an RNS announcing a €0.5m multi-year deal with Global Pharma company Merck (NYSE:MRK) Mkt Cap $152bn htTps:// "Physiomics believes that the Agreement represents a significant external validation of its Virtual Tumour technology by Merck." Physiomics are also talking to 58 other potential clients. Several deals are believed to be 'imminent' Further to this Physiomics in January 2017 were awarded a £200k Government grant to work on a Project with Oxford University Cancer specialists to develop a Cancer DSS (Decision Support System) tool. htTps:// "The project is titled "Decision Support Systems For Stratified Cancer Treatment". In line with the Company's strategic objective to explore the personalised medicine market set out in its full year results (published on the 27th October 2016), the objective of the project is to create a prototype decision support system to improve cancer care by helping medical professionals make treatment decisions based on patient specific data." This 12 month project is set to complete in January 2018. Feedback has been promising and the Company believe they can access 'SUBSTANTIAL NON-DILUTIVE FUNDING' from the Government to continue this project. The ex-Founder of Physiomics has been active on the PYC BB this week and stated that he believes the Company could be valued at north of £1 per share. For valuation comparison :- Oncimmune (ONC) Mkt Cap £65m Revenue £0.1m Physiomics (PYC) Mkt Cap £4m Revenue £0.7m
pwhite73: I don't hear anybody giving me a big round of applause for predicting exactly what would happen here. The RNS has confirmed exactly what I had stated, technically nothing has changed. In my opinion the company is only worth about £750k Now regarding the share price. As previously stated the company has played no part in the meteoric rise it is solely down to the tactics of the MM, professional investors, social media ramping and mug punters. There is nothing like the required amount of shares to go around. The MM will muck about with the share price to sting longs and shorts alike. However in the medium term the share price is heading down for the company is about 20 times overvalued. If you want to know where putting your investment faith in Peter Hoskins can lead to look up a company called EIRX Therapeutics or BillamAG for that matter.
walbrock82: I can’t see why this company exist in the market because it’s a company that fails to make significant inroads. Now it reports falling revenue of 9% to £270k, as operating loss increases to half million pounds. Physiomics is burning between £350k-£450k per year in cash and has become a serial share issuer to the small financial institutions. Share price The share price resembles that of Enron. Three or four years ago, this stock trades around 20 to 30 pence. Now, it’s one penny! The continuous placing means there isn’t anything special. Because if there was, then the big boys would have jumped over this and self-funded the operations. Their latest placing to raise over £500k at £0.025 is a discount of 60% or more to the current share price. This means the financial institutions only have confidence in buying at a huge discount and flipping it back to the market for 250% or more in profit. Meanwhile, the shareholders suffer from the continuous decline in the share price. Final Thoughts Physiomics is a big avoid for retail shareholders because the low market capitalisation of £500k has given retail investors the visual image of seeing this rise by 100%-200%. My advice is to avoid the shares, but if there is a probability this company makes £3m-£4m in sales in the next five years and generate a decent profit of £1m, then a market capitalisation of £5m (10-bagger) or £10m (20-bagger). The odds of that happening is rather small. Therefore, this is a speculative investment where the small financial institutions are making the two to three-baggers! Interested in other companies’ updates and results, then click
Physiomics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180118 08:11:51